{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T09:09:44Z","timestamp":1785143384594,"version":"3.55.0"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The meta-analysis assesses the efficacy and safety of first-line immune checkpoint inhibitors (ICIs) plus anti-angiogenic therapies versus sunitinib in advanced or metastatic renal cell carcinoma (RCC). The analysis places focus on differential benefits across International Metastatic RCC Database Consortium (IMDC) risk subgroups, ICI classes, and anti-angiogenic drug classes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched the Cochrane Library, Embase and PubMed for randomized controlled trials (RCTs) comparing ICI plus anti-angiogenic therapy with sunitinib as first-line treatment for advanced RCC. Efficacy measures included progression-free survival (PFS) and overall survival (OS), objective response rate (ORR), disease control rate (DCR). Safety measures assessed grade \u22653 treatment-related adverse events (TRAEs) and TRAEs leading to discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Seven RCTs involving 4,977 patients were included. Combination therapy was associated with significant improvements in PFS (0.63, [0.54\u20130.72]), OS (0.83, [0.77\u20130.89]), ORR (3.07, [2.01\u20134.67]), and DCR (2.04, [1.49\u20132.78]) (all\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001). OS benefits were most marked in poor-risk (HR = 0.52) and intermediate-risk (HR = 0.88) patients, while favorable-risk patients showed no significant OS gain (0.97, [0.79\u20131.18]). Multi-targeted tyrosine kinase inhibitor (TKI)-based regimens provided the greatest PFS and ORR benefits but the highest toxicity, while vascular endothelial growth factor receptor (VEGFR)-selective TKIs showed a balanced efficacy-safety profile. Anti-VEGF monoclonal antibody-based combinations failed to demonstrate significant OS or ORR advantages over sunitinib. Safety analysis showed no significant difference in grade \u22653 TRAEs (1.22, [0.94\u20131.58]), but did reveal a significantly increased risk of treatment discontinuation (3.34, [2.77\u20134.03]). Additionally, elevated risks of hepatotoxicity, hypertension, and proteinuria were observed, whereas hematologic toxicities and fatigue were significantly reduced versus sunitinib.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>TKI-based ICI combination therapy is superior to sunitinib as first-line treatment for advanced RCC, particularly in intermediate- and poor-risk patients. Anti-angiogenic agent class is the primary determinant of efficacy and tolerability, while ICI class does not influence regimen selection. These findings support a risk-adapted, class-informed approach to optimize therapeutic outcomes in clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review registration<\/jats:title>\n                    <jats:p>Identifier CRD420251273931.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1850724","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T08:33:50Z","timestamp":1785141230000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["First-line immune checkpoint inhibitor plus anti-angiogenic therapy for advanced renal cell carcinoma: a meta-analysis of randomized controlled trials"],"prefix":"10.3389","volume":"17","author":[{"given":"Zijing","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1158\/0008-5472.can-20-2426","article-title":"Inhibition of FGFR reactivates IFN\u03b3 signaling in tumor cells to enhance the combined antitumor activity of lenvatinib with anti-PD-1 antibodies","volume":"82","author":"Adachi","year":"2022","journal-title":"Cancer Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1080\/1744666X.2016.1214575","article-title":"PD-1\/PD-L1 blockade in renal cell cancer","volume":"13","author":"Beckermann","year":"2017","journal-title":"Expert Rev. Clin. Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1158\/1535-7163.MCT-18-1399","article-title":"Cabozantinib in combination with immunotherapy for advanced renal cell carcinoma and urothelial carcinoma: rationale and clinical evidence","volume":"18","author":"Bergerot","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"B4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.euros.2021.12.007","article-title":"Efficacy and safety of first-line systemic therapy for metastatic renal cell carcinoma: a systematic review and network meta-analysis","volume":"37","author":"Bosma","year":"2022","journal-title":"Eur. Urol. Open Sci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/jco.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s40259-020-00449-4","article-title":"The immunotherapy landscape in renal cell carcinoma","volume":"34","author":"Brown","year":"2020","journal-title":"BioDrugs"},{"key":"B7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ctrv.2015.11.003","article-title":"Lenvatinib: role in thyroid cancer and other solid tumors","volume":"42","author":"Cabanillas","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"B8","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/s1470-2045(16)30107-3","article-title":"Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial","volume":"17","author":"Choueiri","year":"2016","journal-title":"Lancet Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.annonc.2024.12.008","article-title":"Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial","volume":"36","author":"Choueiri","year":"2025","journal-title":"Ann. Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/ki.2009.296","article-title":"The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy","volume":"76","author":"Clark","year":"2009","journal-title":"Kidney Int."},{"key":"B11","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12885-025-15462-5","article-title":"Immunotherapy combinations in favourable risk score metastatic renal cell carcinoma, an individual patients data metanalysis","volume":"26","author":"Di Civita","year":"2026","journal-title":"BMC Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e77","DOI":"10.3324\/haematol.2014.117028","article-title":"Inhibition of c-Kit by tyrosine kinase inhibitors","volume":"100","author":"Galanis","year":"2015","journal-title":"Haematologica"},{"key":"B13","doi-asserted-by":"publisher","first-page":"34771","DOI":"10.1038\/s41598-025-18590-x","article-title":"Comparison of inflammatory and nutritional markers obtained at the time of diagnosis in patients diagnosed with renal cell carcinoma","volume":"15","author":"Goksen","year":"2025","journal-title":"Sci. Rep."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann. Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1007\/s10147-016-0959-z","article-title":"PD-1\/PD-L1 blockade in cancer treatment: perspectives and issues","volume":"21","author":"Hamanishi","year":"2016","journal-title":"Int. J. Clin. Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.clgc.2017.07.021","article-title":"Characterization of patients with poor-risk metastatic renal-cell carcinoma: results from a pooled clinical trials database","volume":"16","author":"Hamieh","year":"2017","journal-title":"Clin. Genitourin. Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"Bmj"},{"key":"B18","doi-asserted-by":"publisher","first-page":"231","DOI":"10.4103\/iju.IJU_153_20","article-title":"CheckMate 214 trial: immune checkpoint regulators for advanced renal cell carcinoma","volume":"36","author":"Jena","year":"2020","journal-title":"Indian J. Urol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s12272-022-01389-z","article-title":"Crosstalk between angiogenesis and immune regulation in the tumor microenvironment","volume":"45","author":"Kim","year":"2022","journal-title":"Arch. Pharm. Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1038\/s12276-020-00500-y","article-title":"Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity","volume":"52","author":"Lee","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s41419-020-2511-3","article-title":"Anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells","volume":"11","author":"Liu","year":"2020","journal-title":"Cell Death Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.3390\/cancers15041316","article-title":"Downstream targets of VHL\/HIF-\u03b1 signaling in renal clear cell carcinoma progression: mechanisms and therapeutic relevance","volume":"15","author":"Mazumder","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B23","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1200\/JCO.2005.05.179","article-title":"Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma","volume":"23","author":"Mekhail","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1200\/JCO.2005.02.2574","article-title":"Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma","volume":"24","author":"Motzer","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/s0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"B28","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","article-title":"Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial","volume":"16","author":"Motzer","year":"","journal-title":"Lancet Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/nejmoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"","journal-title":"N. Engl. J. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1002\/cncr.34180","article-title":"Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma","volume":"128","author":"Motzer","year":"","journal-title":"Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jamaoncol.2021.5981","article-title":"Final overall survival and molecular analysis in IMmotion151, a phase 3 trial comparing atezolizumab plus bevacizumab vs sunitinib in patients with previously untreated metastatic renal cell carcinoma","volume":"8","author":"Motzer","year":"","journal-title":"JAMA Oncol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1200\/jco.23.01569","article-title":"Lenvatinib plus pembrolizumab versus sunitinib in first-line treatment of advanced renal cell carcinoma: final prespecified overall survival analysis of CLEAR, a phase III study","volume":"42","author":"Motzer","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.annonc.2025.09.006","article-title":"Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial","volume":"37","author":"Motzer","year":"2026","journal-title":"Ann. Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1177\/1756287217748867","article-title":"Cabozantinib in the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor targeted therapy: clinical trial evidence and experience","volume":"10","author":"Osanto","year":"2018","journal-title":"Ther. Adv. Urol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","article-title":"Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1072634","DOI":"10.3389\/fonc.2023.1072634","article-title":"Comparing efficacy and safety of first-line treatment of metastatic renal cell carcinoma: a Bayesian network meta-regression analysis","volume":"13","author":"Qin","year":"2023","journal-title":"Front. Oncol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"5376","DOI":"10.3748\/wjg.v27.i32.5376","article-title":"Immune checkpoint inhibitor-related hepatotoxicity: a review","volume":"27","author":"Remash","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1158\/1078-0432.CCR-06-1989","article-title":"Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions","volume":"13","author":"Rini","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial","volume":"378","author":"Rini","year":"2011","journal-title":"Lancet"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1016\/s0140-6736(19)30723-8","article-title":"Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial","volume":"393","author":"Rini","year":"2019","journal-title":"Lancet"},{"key":"B42","doi-asserted-by":"publisher","first-page":"3475","DOI":"10.1038\/s41591-025-03867-5","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial","volume":"31","author":"Rini","year":"2025","journal-title":"Nat. Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s40264-013-0048-4","article-title":"Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives","volume":"36","author":"Shah","year":"2013","journal-title":"Drug Saf."},{"key":"B44","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.semcancer.2012.06.001","article-title":"The VHL\/HIF axis in clear cell renal carcinoma","volume":"23","author":"Shen","year":"2013","journal-title":"Semin. Cancer Biol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","article-title":"Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management","volume":"8","author":"Shyam","year":"2023","journal-title":"Signal Transduct. Target Ther."},{"key":"B46","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/s41419-020-02749-7","article-title":"Anlotinib suppresses tumor progression via blocking the VEGFR2\/PI3K\/AKT cascade in intrahepatic cholangiocarcinoma","volume":"11","author":"Song","year":"2020","journal-title":"Cell Death Dis."},{"key":"B47","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"B48","doi-asserted-by":"publisher","first-page":"739263","DOI":"10.3389\/fonc.2021.739263","article-title":"Balancing the risk-benefit ratio of immune checkpoint inhibitor and Anti-VEGF combination therapy in renal cell carcinoma: a systematic review and meta-analysis","volume":"11","author":"Tao","year":"2021","journal-title":"Front. Oncol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/sj.bjc.6605813","article-title":"Myelosuppression by sunitinib is flt-3 genotype dependent","volume":"103","author":"van Erp","year":"2010","journal-title":"Br. J. Cancer"},{"key":"B50","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.annonc.2023.09.3108","article-title":"Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study","volume":"35","author":"Yan","year":"2024","journal-title":"Ann. Oncol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s00262-023-03621-1","article-title":"Updated systematic review and network meta-analysis of first-line treatments for metastatic renal cell carcinoma with extended follow-up data","volume":"73","author":"Yanagisawa","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1002\/jlb.5ru0222-082r","article-title":"Direct and indirect regulation of the tumor immune microenvironment by VEGF","volume":"111","author":"Zhang","year":"2022","journal-title":"J. Leukoc. Biol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"813","DOI":"10.2147\/itt.s494670","article-title":"Immune checkpoint inhibitor combined with antiangiogenic agent synergistically improving the treatment efficacy for solid tumors","volume":"13","author":"Zhou","year":"2024","journal-title":"Immunotargets Ther."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/s1470-2045(25)00343-2","article-title":"First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial","volume":"26","author":"Zhou","year":"2025","journal-title":"Lancet Oncol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1850724\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T08:33:53Z","timestamp":1785141233000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1850724\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":54,"alternative-id":["10.3389\/fphar.2026.1850724"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1850724","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"article-number":"1850724"}}